Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have multiple myeloma that has come back or stopped responding to treatment, and you have already tried at least 3 different types of treatment, including specific drug types targeting myeloma in different ways (such as bortezomib or carfilzomib, daratumumab, and a BCMA-targeted therapy).
- Your myeloma can be measured through at least one blood test, urine test, bone marrow sample, or biopsy showing the disease is still active.
- You are at least 18 years old.
- You are generally well enough to carry out light activity and care for yourself (confirm with trial site what this means for your situation).
- Your kidneys, liver, lungs, and heart are all working well enough to meet specific tested levels (confirm with trial site for exact details).
- If you can become pregnant, or if your partner can become pregnant, you must agree to use at least 2 forms of contraception — including one barrier method — starting before joining the trial and continuing for 12 months after treatment.
- You are able to understand the trial and willing to sign a consent form agreeing to take part.
Who may not be able to join:
- You have received any myeloma treatment within the 14 days before the planned cell collection procedure.
- You have a history of another cancer, unless it was a treated skin cancer (non-melanoma) or a cancer that was fully treated at least 2 years ago with no signs of return.
- You are currently taking part in another clinical trial using an experimental treatment.
- You have received a cell-based therapy within the 8 weeks before the planned start of the preparatory treatment for this trial.
- You have had a serious allergic reaction to treatments similar to the one being studied (confirm with trial site).
- You have previously had a severe reaction (Grade 3 or higher) to another CAR-T cell therapy, including BCMA CAR-T treatments.
- You currently have active hepatitis B, active hepatitis C, HIV, or any infection that is not under control.
- You have an ongoing infection or other serious health condition that could make it unsafe to receive the trial treatment.
- You are pregnant or breastfeeding; women who could become pregnant must have a negative pregnancy test within 14 days of starting the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Armin Ghobadi, M.D., Washington University School of Medicine
Phone: 314-747-2743
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part A: Frequency and severity of treatment-emergent adverse events; Part A: Frequency of dose-limiting toxicities (DLTs); Part B: Frequency and severity of treatment-emergent adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.